Abstract
The increasing prevalence of obesity has significant implications for healthcare, more particularly since it is a major risk factor for type 2 diabetes and cardiovascular diseases. However, not every obese patient is at the same risk of developing future metabolic and cardiovascular complications. Therefore, there is an urgent need for novel biomarkers for early identification of obese patients at high risk. Possible candidate biomarkers are microRNAs, which are highly conserved non-coding RNA molecules of approximately 22 nucleotides that exert post-transcriptional effects on gene expression. They are expressed in a tissue- and cell-type specific manner, play essential roles in many biological and pathological processes and are released in human peripheral blood in a disease-specific manner where they remain stable due to association with lipoprotein and phospholipids. All these characteristics suggest that they are putative diagnostic biomarkers. This review summarizes microRNAs with a functional role in the pathogenesis of atherosclerosis, myocardial infarction, ischemia/reperfusion injury and cardiac remodeling. It emphasizes those which have already been deregulated in association with obesity-related risk factors clustered in the metabolic syndrome. It demonstrates that several microRNAs which have been claimed to be biomarkers for cardiovascular diseases have already been deregulated in association with metabolic disorders prior to cardiovascular diseases. Finally, it summarizes which of these functionally validated microRNAs are deregulated in the circulation making them easily accessible for detection and thus into candidate biomarkers for early diagnosis of obesity-induced cardiovascular events.
Keywords: microRNA, atherosclerosis, cardiovascular diseases, obesity, metabolic syndrome, biomarker.
Current Pharmaceutical Design
Title:MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Volume: 19 Issue: 32
Author(s): Maarten Hulsmans and Paul Holvoet
Affiliation:
Keywords: microRNA, atherosclerosis, cardiovascular diseases, obesity, metabolic syndrome, biomarker.
Abstract: The increasing prevalence of obesity has significant implications for healthcare, more particularly since it is a major risk factor for type 2 diabetes and cardiovascular diseases. However, not every obese patient is at the same risk of developing future metabolic and cardiovascular complications. Therefore, there is an urgent need for novel biomarkers for early identification of obese patients at high risk. Possible candidate biomarkers are microRNAs, which are highly conserved non-coding RNA molecules of approximately 22 nucleotides that exert post-transcriptional effects on gene expression. They are expressed in a tissue- and cell-type specific manner, play essential roles in many biological and pathological processes and are released in human peripheral blood in a disease-specific manner where they remain stable due to association with lipoprotein and phospholipids. All these characteristics suggest that they are putative diagnostic biomarkers. This review summarizes microRNAs with a functional role in the pathogenesis of atherosclerosis, myocardial infarction, ischemia/reperfusion injury and cardiac remodeling. It emphasizes those which have already been deregulated in association with obesity-related risk factors clustered in the metabolic syndrome. It demonstrates that several microRNAs which have been claimed to be biomarkers for cardiovascular diseases have already been deregulated in association with metabolic disorders prior to cardiovascular diseases. Finally, it summarizes which of these functionally validated microRNAs are deregulated in the circulation making them easily accessible for detection and thus into candidate biomarkers for early diagnosis of obesity-induced cardiovascular events.
Export Options
About this article
Cite this article as:
Hulsmans Maarten and Holvoet Paul, MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/13816128113199990364
DOI https://dx.doi.org/10.2174/13816128113199990364 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders
Current Pharmaceutical Design Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews Roles of SUMOylation in Heart Development and Cardiovascular Diseases
Current Molecular Medicine Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design Editorial [ Receptor for Advanced Glycation Endproducts (RAGE): Coming Full Circle in Unraveling the Pathogenesis of Chronic Disease Guest Editor: Ann Marie Schmidt ]
Current Molecular Medicine Role of Statins in Diabetes Complications
Current Diabetes Reviews Nitroxides as Cancer Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Mesenchymal Stem Cells: Promising for Myocardial Regeneration?
Current Stem Cell Research & Therapy Radioprotective Effect of Febuxostat Against Testicular Damage Induced by Ionizing Radiation in Mice
Current Radiopharmaceuticals Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review
Current Neuropharmacology Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design miR-15b Suppression of Bcl-2 Contributes to Cerebral Ischemic Injury and is Reversed by Sevoflurane Preconditioning
CNS & Neurological Disorders - Drug Targets Tissue Plasminogen Activator Prevents Restoration of Tight Junction Proteins Through Upregulation of Angiopoietin-2
Current Neurovascular Research Oxidative Stress-Induced Ischemic Heart Disease: Protection by Antioxidants
Current Medicinal Chemistry Carbon Monoxide - Toxicity of Low-Dose Application
Current Pharmaceutical Biotechnology Equol is Neuroprotective During Focal Cerebral Ischemia and Reperfusion that Involves p-Src and gp91<sup>phox</sup>
Current Neurovascular Research